INAB
IN8bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.20
+3.45%Margins
Gross margin
—
EBITDA margin
—
EBIT margin
—
Net margin
—
FCF margin
—
-101.7%
Return on equity
-85.8%
Return on assets
-91.7%
Return on invested capital
0.00x
Asset turnover
-$14.4M
Cash from operations
$1.82
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026